Trending:
The US Food and Drug Administration (FDA) has granted priority review for Roche’s Tecentriq (atezolizumab) in combination with chemotherapy for treating extensive-stage small cell lung cancer (ES - SCLC).
Japanese pharmaceutical company Eisai has expanded its drug discovery collaboration with University College London (UCL) in the UK for additional five years to 2023.
Mylan has expanded the consumer-level voluntary recall of all lots of valsartan-containing drugs within expiry in the US after finding trace amounts of an impurity called N-nitrosodiethylamine (NDEA).
Takeda Pharmaceutical has secured shareholder approval for the issuance of its shares necessary to implement the proposed $62bn acquisition of Shire.
Boehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs to treat central nervous system (CNS) diseases.
Belgian biopharmaceutical company UCB has agreed to invest approximately £1bn ($1.27bn) as part of a collaboration between the UK government and life sciences industry intended to support healthcare innovation in...
The US Food and Drug Administration (FDA) has granted San Francisco-based Global Blood Therapeutics (GBT)’s sickle cell disease (SCD) therapy voxelotor an accelerated approval under the subpart H pathway.
A new report by The Institute of Cancer Research, London (ICR) has revealed an increase of nearly one year in delay between clinical trials, regulatory approvals and patient access to...
Janssen Pharmaceutical affiliate Cilag International has signed a global collaboration and license agreement with Dutch biotechnology company Argenx for cusatuzumab (ARGX-110) therapeutic.
GlaxoSmithKline (GSK) has signed a merger agreement to buy US-based biopharmaceutical company Tesaro for an aggregate consideration of around $5.1bn in a cash-based transaction.
Go Top
